Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · IEX Real-Time Price · USD
19.22
-0.25 (-1.28%)
May 2, 2024, 4:00 PM EDT - Market closed
Myriad Genetics Employees
Myriad Genetics had 2,700 employees on December 31, 2023. The number of employees increased by 100 or 3.85% compared to the previous year.
Employees
2,700
Change (1Y)
100
Growth (1Y)
3.85%
Revenue / Employee
$278,963
Profits / Employee
-$97,519
Market Cap
1.73B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2,700 | 100 | 3.85% |
Dec 31, 2022 | 2,600 | 200 | 8.33% |
Dec 31, 2021 | 2,400 | -300 | -11.11% |
Jun 30, 2020 | 2,700 | 100 | 3.85% |
Jun 30, 2019 | 2,600 | 200 | 8.33% |
Jun 30, 2018 | 2,400 | 0 | - |
Jun 30, 2017 | 2,400 | 194 | 8.79% |
Jun 30, 2016 | 2,206 | 168 | 8.24% |
Jun 30, 2015 | 2,038 | 389 | 23.59% |
Jun 30, 2014 | 1,649 | 324 | 24.45% |
Jun 30, 2013 | 1,325 | 156 | 13.34% |
Jun 30, 2012 | 1,169 | 112 | 10.60% |
Jun 30, 2011 | 1,057 | 187 | 21.49% |
Jun 30, 2010 | 870 | 1 | 0.12% |
Jun 30, 2009 | 869 | -125 | -12.58% |
Jun 30, 2008 | 994 | 146 | 17.22% |
Jun 30, 2007 | 848 | 126 | 17.45% |
Jun 30, 2006 | 722 | 65 | 9.89% |
Jun 30, 2005 | 657 | 146 | 28.57% |
Jun 30, 2004 | 511 | -6 | -1.16% |
Jun 30, 2003 | 517 | 26 | 5.30% |
Jun 30, 2002 | 491 | 39 | 8.63% |
Jun 30, 2001 | 452 | 114 | 33.73% |
Jun 30, 2000 | 338 | 94 | 38.52% |
Jun 30, 1999 | 244 | -26 | -9.63% |
Jun 30, 1998 | 270 | 73 | 37.06% |
Jun 30, 1997 | 197 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
NeoGenomics | 2,100 |
Twist Bioscience | 919 |
Schrödinger | 867 |
Alphatec Holdings | 839 |
Supernus Pharmaceuticals | 652 |
Beam Therapeutics | 507 |
Harmony Biosciences Holdings | 246 |
Catalyst Pharmaceuticals | 167 |
MYGN News
- 2 days ago - Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024 - GlobeNewsWire
- 15 days ago - Nearly Half of Americans Say They've Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor - GlobeNewsWire
- 16 days ago - New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen - GlobeNewsWire
- 23 days ago - Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing - GlobeNewsWire
- 6 weeks ago - Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date - GlobeNewsWire
- 6 weeks ago - Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device - GlobeNewsWire
- 2 months ago - Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance - GlobeNewsWire
- 2 months ago - Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3 - GlobeNewsWire